2011
Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells
Lee HG, Minematsu H, Kim KO, Aydemir A, Shin MJ, Nizami SA, Chung KJ, Hsu AC, Jacobs CR, Lee FY. Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. Biomaterials 2011, 32: 9197-9206. PMID: 21899882, PMCID: PMC3193180, DOI: 10.1016/j.biomaterials.2011.08.059.Peer-Reviewed Original ResearchMeSH KeywordsActinsAdhesivenessAnimalsBenzimidazolesBone and BonesCCAAT-Enhancer-Binding Protein-betaCyclooxygenase 2Cytochalasin DExtracellular Signal-Regulated MAP KinasesGene Expression RegulationHumansImmunity, InnateInflammationInterleukin-6MAP Kinase Signaling SystemMiceModels, BiologicalOsteogenesisOsteolysisPhagocytosisProtein Kinase InhibitorsSignal TransductionSkullStem CellsTime FactorsTitaniumConceptsInflammatory osteolysisInflammatory responseMacrophage-mediated inflammatory responsesKey inflammatory pathwaysSuitable therapeutic targetInflammatory gene expressionInnate immune responseOsteoprogenitor cellsInflammatory cascadeInflammatory pathwaysImmune responseTherapeutic targetHost bone-implant interfaceAZD6244 treatmentIntracellular mechanismsBone-implant interfaceBone formationCellular mechanismsERK pathwayInflammationΒ pathwayOsteoclastogenesisOsteolysisIntracellular signalingImplant osteointegration
2009
Zoledronate reduces unwanted bone resorption in intercalary bone allografts
Seo SW, Cho SK, Storer SK, Lee FY. Zoledronate reduces unwanted bone resorption in intercalary bone allografts. International Orthopaedics 2009, 34: 599-603. PMID: 19343345, PMCID: PMC2903128, DOI: 10.1007/s00264-009-0748-7.Peer-Reviewed Original ResearchConceptsAllograft resorptionIntercalary allograftsBone resorptionBone allograftControl groupZoledronate solutionIntercalary bone allograftsBone formationBone mineral densitySynthetic pyrophosphate analoguesHigh-dose bisphosphonatesPharmacological modificationGraft incorporationMineral densityBone densityAllograftsIdeal doseResorptionAnimal trialsHistological analysisBisphosphonatesSegmental defectsPyrophosphate analogsExperimental groupRat femur